Atypical fibroxanthoma: A histological and immunohistochemical review of 171 cases

American Journal of Dermatopathology

Volumn 32, Issue 6, 2010, Pages 533-540

  Beer, Trevor W ^a   Drury, Paul ^a   Heenan, Peter J ^a  

^a Cutaneous Pathology   (Australia)

Author keywords

Atypical fibroxanthoma; case series; immunohistochemistry; literature review; misdiagnosis

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL FIBROXANTHOMA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOLOGY; FEMALE; FIBROXANTHOMA; GRANULAR CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KELOID; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; PRIORITY JOURNAL; SKIN BIOPSY; SOLAR RADIATION; SPINDLE CELL; SUBCUTANEOUS TISSUE;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955175287     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181c80b97     Document Type: Article

References (57)

1. Beer TW, Lam M, Heenan PJ. Fibrous tissue tumors of the skin. In: Elder DE. Lever's Histopathology of the Skin. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009:978-979.
2. Weiss SW, Goldblum JR. Atypical fibroxanthoma. In: Enzinger and Weiss's Soft Tissue Tumors. 5th ed. Mosby; 2008:403-406.
3. Beer TW. Squamous cell carcinoma with osteoclast-like giant cells: 2 cases misdiagnosed as atypical fibroxanthoma. Am J Dermatopathol. In press.
4. Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005;46:235-238.
5. Beer TW. Keloidal and granular cell change in a series of 171 atypical fibroxanthomas. J Cutan Pathol. In press.
6. Beer TW, Haig D. CD117 is not a useful marker in atypical fibroxanthoma. Am J Dermatopathol. 2009;31:649-652.
7. Alguacil-Garcia A, Unni KK, Goellner JR, et al. Atypical fibroxanthoma ofthe skin: an ultrastructural study oftwo cases. Cancer. 1977;40:1471-1480.
8. Barr RJ, Wuerker RB, Graham JH. Ultrastructure of atypical fibroxanthoma. Cancer. 1977;40:736-743.
9. Longacre TA, Smoller BR, Rouse RU. Atypical fibroxanthoma: multiple immunohistologic profiles. Am J Surg Pathol. 1993;17:1199-1209.
10. Carless MAK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol. 1992;97:478-483.
11. Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16:213-228.
12. Fletcher CDM. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3-12.
13. Hollowood K, Fletcher CDM. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Semin Diagn Pathol. 1995;12:210-220.
14. Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20:749-759.
15. Pezzi CM, Rawlings MS Jr, Esgro JJ, et al. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098-2103.
16. Weiss SW. Malignant fibrous histiocytoma. Am J Surg Pathol. 1982;6: 773-784.
17. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250-2266.
18. Sakamoto A, Oda Y, Itakura E, et al. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol. 2001;32:1225-1231.
19. Oshiro Y, Fukuda T, Tsuneyoshi M. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Cancer. 1995;75:1128-1134.
20. Lazova R, Moynes R, May D, et al. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79:2115-2124.
21. Worrell JT, Ansari MQ, Ansari SJ, et al. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications. J Cutan Pathol. 1993;20:211-215.
22. Merot Y, Durgniat AC, Frenk E. Nucleolar organizer regions in fibrohistiocytic tumors of the skin. J Cutan Pathol. 1990;17:122-126.
23. Westermann FN, Langlois NE, Simpson JG. Apoptosis in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma. Am J Dermatopathol. 1997;19:228-231.
24. Dahl I. Atypical fibroxanthoma of the skin. A clinico-pathological study of 57 cases. Acta Pathol Microbiol Scand [A]. 1976;84:183-197.
25. Evans HL, Smith JL. Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases. Cancer. 1980;45: 2687-2697.
26. Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer. 1973;31:1541-1552.
27. Leong AS, Milios J. Atypical fibroxanthoma of the skin: a clinicopath- ological and immunohistochemical study and a discussion of its histogenesis. Histopathology. 1987;11:463-475.
28. English DR, Kricker A, Heenan PJ, et al. Incidence of non-melanocytic skin cancer in Geraldton, Western Australia. Int J Cancer. 1997;73: 629-633.
29. Threlfall TJ, Thompson JR. Cancer Incidence and Mortality in Western Australia, 2005. Department of Health, Western Australia, Perth, Australia; 2007. Statistical Series Number 81.
30. Starink TH, Hausman R, Van Delden L, et al. Atypical fibroxanthoma of the skin. Presentation of 5 cases and a review of the literature. Br J Dermatol. 1977;97:167-177.
31. Weiss SW, Goldblum JR. Malignant fibrous histiocytoma. In: Enzinger and Weiss's Soft Tissue Tumors. 5th ed. Mosby; 2008:406-425.
32. Ang GC, Roenigk RK, Otley CC, et al. More than 2 decades of treating atypical fibroxanthoma at Mayo clinic: what have we learned from 91 patients? Dermatol Surg. 2009;35:765-772.
33. Davis JL, Randle HW, Zalla MJ, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg. 1997;23:105-110.
34. Seavolt M, McCall M. Atypical fibroxanthoma: review of the literature and summary of 13 patients treated with mohs micrographic surgery. Dermatol Surg. 2006;32:435-441.
35. Calonje E, Wadden C, Wilson-Jones E, et al. Spindle-cell non- pleomorphic atypical fibroxanthoma: analysis of a series and delineation of a distinctive variant. Histopathology. 1993;22:247-254.
36. Kemmerling R, Dietze O, Miiller S, et al. Aspects of the differential diagnosis of clear-cell lesions of the skin in connection with the rare case of a clear-cell atypical fibroxanthoma. Pathol Res Pract. 2009;205:365-370.
37. Wright NA, Thomas CG, Calame A, et al. Granular cell atypical fibroxanthoma: case report and review of the literature. J Cutan Pathol. 2009;36:1177-1184.
38. Patton A, Page R, Googe P, et al. Myxoid atypical fibroxanthoma: a previously undescribed variant. J Cutan Pathol. 2009. Epub ahead of print.
39. Ferrara N, Baldi G, Di Marino MP, et al. Atypical fibroxanthoma with osteoclast-like multinucleated giant cells. In Vivo. 2000;14:105-107.
40. Khan ZM, Cockerell CJ. Atypical fibroxanthoma with osteoclast-like multinucleated giant cells. Am J Dermatopathol. 1997;19:174-179.
41. Orlandi A, Bianchi L, Ferlosio A, et al. The origin of osteoclast-like giant cells in atypical fibroxanthoma. Histopathology. 2003;42:407-410.
42. Tomaszewski MM, Lupton GP. Atypical fibroxanthoma. An unusual variant with osteoclast-like giant cells. Am J Surg Pathol. 1997;21:213-218.
43. Val-Bernal JF, Corral J, Fernandez F, et al. Atypical fibroxanthoma with osteoclast-like giant cells. Acta Derm Venereol. 1994;74:467-470.
44. Wilson PR, Strutton GM, Stewart MR. Atypical fibroxanthoma: two unusual variants. J Cutan Pathol. 1989;16:93-98.
45. Zelger BG, Soyer HP, Zelger B. Giant cell atypical fibroxanthoma: does it really exist? Am J Dermatopathol. 1999;21:108-110.
46. Kim J, McNiff JM. Keloidal atypical fibroxanthoma: a case series. J Cutan Pathol. 2009;36:535-539.
47. Stefanato C, Robson A, Calonje E. The histopathological spectrum of atypical fibroxanthoma with regression. J Cutan Pathol. 2009;36:166. Abstract.
48. Bruecks AK, Medlicott SA, Trotter MJ. Atypical fibroxanthoma with prominent sclerosis. J Cutan Pathol. 2003;30:336-339.
49. Dettrick A, Strutton G. Atypical fibroxanthoma with perineural or intra- neural invasion: report of two cases. J Cutan Pathol. 2006;33:318-322.
50. McKee PH, Calonje E, Granter SR. Fibrohistiocytic tumors. In: Pathology of the Skin. 3rd ed. Philadelphia, PA: Elsevier Mosby; 2005:1757-1760.
51. Ricci A Jr, Cartun RW, Zakowski MF. Atypical fibroxanthoma. A study of 14 cases emphasizing the presence of Langerhans' histiocytes with implications for differential diagnosis by antibody panels. Am J Surg Pathol. 1988;12:591-598.
52. Zelger B, Soyer HP. Between Scylla and Charybdis: mythology in dermatopathology. Dermatopathol Pract Concept. 2000;6:348-355.
53. Gray Y, Robidoux HJ, Farrell DS, et al. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma. Arch Pathol Lab Med. 2001;125:799-802.
54. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2006;33:413-417.
55. Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009;36:543-547.
56. Greene LA, Cooper K. Atypical fibroxanthoma: an immunohistochem- istry update. Adv Anat Pathol. 2008:15;374.
57. Hall JM, Saenger JS, Fadare O. Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas. Int J Clin Exp Pathol. 2008;1:524-530.